Close Menu

Helicos

The Massachusetts sequencing firm has been selling technology originally developed by Helicos BioSciences and planned to increase marketing with the IPO proceeds.

The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of  the test as an LDT.

The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.

The company is currently working with three hospitals in China and plans to launch the GenoCare system commercially in 2017.

This article was originally published Sept. 29.

NEW YORK (GenomeWeb) – Startup SeqLL has closed a $1 million Series A financing round, which it said it will use to enhance Helicos BioSciences' single-molecule sequencing technology for scientific and diagnostic applications. Genomic Diagnostic Technologies led the investment.

Authors of a recent study in BMC Research Notes have concluded that archeological control testing and targeted verification testing are key to avoiding false-positive pathogen identification when

NEW YORK (GenomeWeb News) – Researchers at Brown University and the St. Laurent Institute have found ties between RNA editing and transposon-related gene silencing in fruit flies — findings that they suspect may extend to other organisms.

NEW YORK (GenomeWeb News) – The US bankruptcy court in charge of Helicos BioSciences' Chapter 11 bankruptcy reorganization has approved deals for the company to license its intellectual pr

NEW YORK (GenomeWeb News) – Defunct next-generation sequencing technology firm Helicos BioSciences has asked a bankruptcy court to approve the licensing of intellectual property to Illumina, Life Technologies, and Fluidigm.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.